X4 Pharmaceuticals Newsroom

B.Riley Financial Maintains X4 Pharmaceuticals(XFOR.US) With Hold Rating, Cuts Target Price to $0.5

Moomoo NewsNov 19 03:39 ET

B. Riley Adjusts X4 Pharmaceuticals Price Target to $0.50 From $1, Maintains Neutral Rating

MT NewswiresNov 18 09:02 ET

HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $1.5

BenzingaNov 14 13:10 ET

X4 Pharmaceuticals Is Maintained at Buy by Stifel

Dow JonesNov 14 05:03 ET

X4 Pharmaceuticals Analyst Ratings

BenzingaNov 14 04:53 ET

X4 Pharmaceuticals (XFOR) Gets a Buy From Piper Sandler

TipRanksAug 9 08:57 ET

Buy Rating Affirmed on X4 Pharmaceuticals: A Comprehensive Analysis of Financial Stability and Drug Development Progress

TipRanksAug 9 07:20 ET

X4 Pharmaceuticals Analyst Ratings

BenzingaJun 28 07:40 ET

X4 Pharmaceuticals Analyst Ratings

BenzingaMay 31 11:00 ET

X4 Pharmaceuticals (XFOR) Gets a Buy From Piper Sandler

TipRanksMay 8 07:22 ET

Optimistic Buy Rating for X4 Pharmaceuticals Following FDA Approval and Strong Clinical Prospects

TipRanksMay 8 06:31 ET

X4 Pharmaceuticals Analyst Ratings

BenzingaApr 30 06:53 ET

Buy Rating Affirmed for X4 Pharmaceuticals' Xolremdi on Robust Clinical Efficacy and Favorable Market Strategy

TipRanksApr 30 06:25 ET

X4 Pharmaceuticals Analyst Ratings

BenzingaMar 22 14:57 ET

Buy Rating Affirmed on X4 Pharmaceuticals Amid Positive Mavorixafor Prospects

TipRanksMar 22 06:35 ET

B. Riley Securities Downgrades X4 Pharmaceuticals to Neutral, Lowers Price Target to $1

BenzingaDec 12, 2023 08:12 ET

X4 Pharmaceuticals Analyst Ratings

BenzingaDec 12, 2023 08:10 ET

Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN), X4 Pharmaceuticals (XFOR) and Dynatronics (DYNT)

TipRanksNov 10, 2023 12:01 ET

Promising Future for X4 Pharmaceuticals: Strong Financials and Potential Drug Launch Drive Buy Rating

TipRanksNov 10, 2023 07:10 ET

TD Cowen Sticks to Their Buy Rating for X4 Pharmaceuticals (XFOR)

TipRanksNov 9, 2023 17:46 ET